Welcome to our dedicated page for Bioharvest SEC filings (Ticker: BHST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioHarvest Sciences Inc. (NASDAQ: BHST) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer. BioHarvest files reports with the U.S. Securities and Exchange Commission that document its Botanical Synthesis biotechnology business, financial condition, and capital markets activity.
BioHarvest uses Form 6-K to furnish current reports, including unaudited interim condensed consolidated financial statements, management’s discussion and analysis for specific periods, material change reports, and news releases. These filings cover topics such as revenue trends from the VINIA nutraceutical brand, the growth of the CDMO Services division, and updates on technology initiatives like plant-based exosomes and saffron-derived compounds developed with partners.
The company also references its annual reporting on Form 40-F and a shelf registration statement on Form F-3, which supports public offerings of common stock. Related prospectus supplements and underwriting agreements are incorporated into 6-K submissions, providing detail on how BioHarvest raises capital to fund manufacturing expansion, research and development, marketing, and general corporate purposes.
On Stock Titan, AI-powered tools can help interpret BioHarvest’s filings by summarizing key points from lengthy financial statements and management discussions, highlighting items such as segment performance, non-IFRS measures like Adjusted EBITDA, and material changes reported to regulators. Users can also track ongoing 6-K submissions to follow new grants, strategic CDMO contracts, and other disclosed events that shape the company’s Botanical Synthesis and nutraceutical strategy.
BioHarvest Sciences shares a year-end update highlighting its first full year as a Nasdaq-listed company, with an annualized revenue run rate above
The VINIA-branded direct-to-consumer line now has more than 85,000 active users, over 90% of Vinia.com sales via subscriptions, and a 4.7/5 rating from more than 10,000 reviews. The CDMO Services division signed anchor contracts across several industries, began work on two major plant-based compounds, and expects its revenues to eventually surpass the products division. The company plans to invest in a 100-ton manufacturing footprint and targets adjusted EBITDA breakeven while pursuing growth from both its D2C and CDMO businesses.
BioHarvest Sciences Inc. (BHST) launched a primary offering of 2,485,000 common shares. The shares are priced at $7.00 each, for gross proceeds of $17,395,000, less underwriting discounts of $1,192,688, with estimated net proceeds of approximately $15,802,200. The company granted a 30‑day option to the underwriter to purchase up to 372,750 additional shares.
Shares outstanding are expected to be 19,818,430 after the offering (or 20,191,180 if the option is fully exercised). Craig‑Hallum is the sole managing underwriter, with delivery expected on or about November 10, 2025. The company plans to use the proceeds for research and development, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes.
BioHarvest also provided preliminary results: Q3 2025 revenue is expected to be approximately $9.1M with adjusted EBITDA between negative $0.7M and negative $0.4M. Q4 2025 guidance calls for revenue of $9.0M to $9.5M and adjusted EBITDA between negative $0.6M and $0.0M.
BioHarvest Sciences Inc. launched a preliminary prospectus supplement for a primary underwritten offering of common shares on Nasdaq under “BHST,” with Craig‑Hallum as sole managing underwriter and a 30‑day option for the underwriter to buy additional shares after effectiveness. The company, a foreign private issuer and emerging growth company, plans to use proceeds for research and development, manufacturing, marketing, advancing its CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes.
Management also shared preliminary Q3 2025 results and Q4 guidance. Q3 revenue is expected at approximately $9.1M, with adjusted EBITDA in a range of ($0.7M) to ($0.4M). For Q4 2025, revenue guidance is $9.0M to $9.5M, with adjusted EBITDA between ($0.6M) and $0.0M. Recently, the company signed a CDMO agreement with Saffron Tech to develop saffron‑derived compounds; Saffron Tech will own 75% of developed compositions and related IP, while BioHarvest will hold 25% and intends to manufacture and market resulting products.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
